1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDisease
1987
Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease
Blayney D, Longo D, Young R, Greene M, Hubbard S, Postal M, Duffey P, DeVita V. Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. New England Journal Of Medicine 1987, 316: 710-714. PMID: 3821809, DOI: 10.1056/nejm198703193161203.Peer-Reviewed Original ResearchConceptsRisk of leukemiaHodgkin's diseaseAcute leukemiaNormal marrow morphologyBone marrow aspirationAcute nonlymphocytic leukemiaSecond neoplasmsMarrow aspirationNonlymphocytic leukemiaMarrow morphologyActuarial analysisPatientsBone marrowFirst treatmentPeak onsetLeukemiaMorphologic changesChemotherapyRadiation treatmentDiseaseComplicationsTreatmentRiskYearsPrevious studies
1977
Characteristics of Blast Crisis in Chronic Granulocytic Leukemia
Rosenthal S, Canellos G, DeVita V, Gralnick H. Characteristics of Blast Crisis in Chronic Granulocytic Leukemia. Blood 1977, 49: 705-714. DOI: 10.1182/blood.v49.5.705.705.Peer-Reviewed Original ResearchCharacteristics of blast crisis in chronic granulocytic leukemia.
Rosenthal S, Canellos G, DeVita V, Gralnick H. Characteristics of blast crisis in chronic granulocytic leukemia. Blood 1977, 49: 705-14. PMID: 265737, DOI: 10.1182/blood.v49.5.705.bloodjournal495705.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaBlast crisisExtramedullary leukemiaGranulocytic leukemiaDiagnosis of blast crisisPh1-positive chronic granulocytic leukemiaLymphoblastic groupAcute leukemiaPeripheral bloodHematological criteriaHematological featuresBone marrowLeukemiaMorphological subgroupsPatientsThrombocytopeniaTerminal phaseMarrow
1976
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug dose